Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0EL5Q
|
|||
| Drug Name |
JTX-2011
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2] | |
| Company |
Jounce Therapeutics Cambridge, MA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inducible T-cell costimulator (ICOS) | Target Info | Agonist | [1], [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| T cell receptor signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Primary immunodeficiency | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.